R&D channel feed

FDA re­buffs lit­tle As­ser­tio Ther­a­peu­tic­s' long-act­ing ACTH for­mu­la­tion, shares sink

6 years ago
FDA+

Failed PhI­II fe­vip­iprant tri­als pour more cold wa­ter on No­var­tis' block­buster R&D en­gine — and briefly spread the chill to a high-pro­file biotech

6 years ago

J&J's block­buster Ste­lara wins US ap­proval for ul­cer­a­tive col­i­tis

6 years ago
Pharma
FDA+

Sofinno­va-backed Abi­vax touts longer term mid-stage da­ta in ul­cer­a­tive col­i­tis

6 years ago

Pfiz­er gets some en­cour­ag­ing PhI­II news on a fran­chise sav­ior, but is a dos­ing ad­van­tage worth the $295M up­front?

6 years ago

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

6 years ago
Pharma
FDA+

IM­brave150: Roche’s reg­u­la­to­ry crew plans a glob­al roll­out of Tecen­triq com­bo for liv­er can­cer as PhI­II scores a hit

6 years ago

FDA ap­proval lets Foamix set its maid­en ac­ne ther­a­py on course for US mar­ket launch

6 years ago

Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

6 years ago

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

6 years ago

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

6 years ago
Pharma
FDA+

Mer­ck is tak­ing the ax to its US op­er­a­tions, cut­ting 500 jobs in its lat­est re­or­ga­ni­za­tion

6 years ago

PhI fiz­zle forces Sy­ros to spike its lead drug, trig­ger­ing an­oth­er rout on shares

6 years ago

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

6 years ago

UCB tries to win some re­spect in the crowd­ed pso­ri­a­sis mar­ket with a dual IL-17 ap­proach — and it won't be easy

6 years ago

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

6 years ago

In­cyte's cash cow Jakafi chugs along with pos­i­tive front­line re­sults for GVHD

6 years ago

With biosim­i­lar threat un­der con­trol (for now), Roche sa­vors de­mand for its new drugs

6 years ago
Pharma

Cell ther­a­py play­er Gam­maDelta spins off Adap­tate to di­rect body's sur­veil­lance sys­tem

6 years ago

Ipsen splurges $25M on its sec­ond rare dis­ease drug pact of the year, with more on the way

6 years ago

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

6 years ago
Pharma

Eli Lil­ly’s first PhI­II show­down for their $1.6B can­cer drug just flopped — what now?

6 years ago

Alex­ion pays $930M to buy out Achillion and its promis­ing com­pan­ion drug to Soliris

6 years ago
Deals

The $102B club: The top 15 R&D spenders in the glob­al bio­phar­ma busi­ness — 2019 edi­tion

6 years ago
Special
First page Previous page 227228229230231232233 Next page Last page
A service from the Financial Times